India Glp-1 Receptor Agonist Market Size & Outlook
India glp-1 receptor agonist market, 2018-2030 (US$M)
Related Markets
India glp-1 receptor agonist market highlights
- The India glp-1 receptor agonist market generated a revenue of USD 105.7 million in 2023 and is expected to reach USD 578.9 million by 2030.
- The India market is expected to grow at a CAGR of 27.5% from 2024 to 2030.
- In terms of segment, trulicity was the largest revenue generating product in 2023.
- Other Products is the most lucrative product segment registering the fastest growth during the forecast period.
Glp-1 receptor agonist market data book summary
| Market revenue in 2023 | USD 105.7 million |
| Market revenue in 2030 | USD 578.9 million |
| Growth rate | 27.5% (CAGR from 2023 to 2030) |
| Largest segment | Trulicity |
| Fastest growing segment | Other Products |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Trulicity, Rybelsus (oral semaglutide), Victoza (liraglutide), Other Products |
Other key industry trends
- In terms of revenue, India accounted for 0.3% of the global glp-1 receptor agonist market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, China glp-1 receptor agonist market is projected to lead the regional market in terms of revenue in 2030.
- India is the fastest growing regional market in Asia Pacific and is projected to reach USD 578.9 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
GLP-1 Receptor Agonist Market Scope
GLP-1 Receptor Agonist Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
India glp-1 receptor agonist market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to glp-1 receptor agonist market will help companies and investors design strategic landscapes.
Trulicity was the largest segment with a revenue share of 81.84% in 2023. Horizon Databook has segmented the India glp-1 receptor agonist market based on trulicity, rybelsus (oral semaglutide), victoza (liraglutide), other products covering the revenue growth of each sub-segment from 2018 to 2030.
India has a robust pharmaceutical sector, which can largely be attributed to the emergence of generic manufacturers and the local presence of leading pharmaceutical companies. The growth of the India GLP-1 receptor agonist market is driven by the increasing prevalence of target diseases in the country, coupled with several government awareness campaigns to promote awareness regarding the conditions.
India is referred to as the “Diabetes Capital of the World,” and it is estimated that one in 11 individuals in the country has diabetes, accounting for 77 million of the total population. Moreover, it makes up 17% of the total diabetes cases across the globe.
The high prevalence of the condition propels the need for the development of effective therapeutics. Key players in the market are actively engaging in strategic initiatives to drive growth, including expanding production capacities, acquiring new companies, and investing in advanced technologies.
Reasons to subscribe to India glp-1 receptor agonist market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of India glp-1 receptor agonist market databook
-
Our clientele includes a mix of glp-1 receptor agonist market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the India glp-1 receptor agonist market , including forecasts for subscribers. This country databook contains high-level insights into India glp-1 receptor agonist market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
India glp-1 receptor agonist market size, by product, 2018-2030 (US$M)
India GLP-1 Receptor Agonist Market Outlook Share, 2023 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
